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1. Introduction 
Alzheimer's Disease is the most common neurodegeneration and the prototype of this 
group of diseases. Now threatens to become an epidemy with a predictable and profound 
impact. 
In 1906 Alois Alzheimer brilliantly defined the clinicopathologic syndrome that now bears 
his name to relate the progression of cognitive impairment to pathological anatomic 
findings wich remains as the markers of the disease: amyloid plaques and neurofibrillary 
tangles. After more than a hundred years since its description, especially in the last two 
decades new interesting clues have been revealed to understanding the basic mechanisms of 
disease. This research highlights the discovery of genes in familial and sporadic forms, the 
description in detail of the beta amyloid cascade and tau protein metabolism and a better 
understanding of the role of vascular factors, inflammation, brain resistance to insulin and 
the recent and intriguing findings about the role of the prion receptors and prion like 
mechanisms in the development of disease. Thus, new actors earn role in the 
pathophysiology of an ancient drama: Alzheimer’s disease. 
This chapter discusses these topics with the assurance that in the coming years will be the 
basis for the development of new diagnostic tools and more effective treatments. 
2. Pathology 
2.1 Macroscopic 
Alzheimer's disease (AD) is characterized by a global involvement, bilateral and 
symmetrical in both hemispheres with cortical predominance. There is reduced 
transparency and fibrosis of the leptomeninges and subarachnoid large gaps remains in the 
spaces left between the cerebral sulci. When the meninges are removed we can see a pale 
brain with weight decrease of approximately 800 to 1000g from 1300 to 1700g in the normal 
adult.  There is greater involvement of the association areas (fronto temporal and parietal) 
and to a lesser degree of primary motor and sensory areas. The most affected region is the 
mesial temporal lobe and especially the entorhinal cortex. The increase of the ventricles is 
secondary to parenchymal loss.  A recent neuroimage-based quantitative meta-analysis 
revealed that early AD affects structurally the hippocampal regions (figures 1.A and 1.B), 
while functionally affects the inferior parietal lobules (figures 1.C and 1.D), which might be 
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caused by regional amyloid deposits and by disconnection from the hippocampus through 
disruption of the cingulum bundle (Schroeter et al., 2009). 
Although not define the disease, there is usually involvement of the subcortical white matter 
leukoaraiosis as well as small infarcts and atherosclerotic changes in large arteries. 
 
 
Fig. 1. Brain MRI (Magnetic Resonance Imaging) and perfusion SPECT (Single Photon 
Emission Computed Tomography) images of a patient with AD in early stage examined in 
our institution (female, age= 66 years, Mini Mental State Examination (MMSE)=22); all 
images are oriented in the radiological convention.  A) Axial view of high resolution MRI 
image (T1) showing brain atrophy, particularly in the hippocampus bilaterally; B) Coronal 
slice at the level of the red line show in the axial view; C)  99mTc–ECD SPECT image using a 
double-head system and corrected for partial volume effect (corrected for atrophy), showing 
regional hypoperfusion in the parietal regions, particularly in the angular gyrus bilaterally; 
and D) Coronal slice at the level of the blue line show in the axial view C. For comparison 
see figure 2 with similar images of a clinically healthy subject.  
 
 
Fig. 2. Brain MRI and perfusion SPECT images of a clinically healthy subject (female,  
age= 64 years, MMSE=30).  A) to D) are similar  images  show in figure 1.    
There are atypical or asymmetric forms where the degeneration and atrophy is restricted to one 
lobe or cerebral hemisphere. A series of cases shows that these phenotypes are not as infrequent 
as it is supposed (Alladi et al., 2007). The pathology of AD is a common substrate in the 
Posterior Cortical Atrophy, Non Fluent Progressive Aphasia and Cortico Basal Degeneration 
although is rare in others such as Semantic Dementia and Fronto Temporal Dementia. In the 
case of Non Fluent Progressive Aphasia most cases corresponds with typical findings of AD.   
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2.2 Microscopic 
Corroborate the findings described above. It were also observed important changes such as 
subcortical neuronal depopulation of the nucleus basalis of Meynert, raphe nuclei, the 
nucleus ceruleus, amygdala, and white matter lesions. The two typical lesions that define 
AD are senile plaques and neurofibrillary tangles: 
2.2.1 Senile Plaques (SP) 
Observed in the interstice, between neurons. They measure between 20 and 100 microns and 
consist of a core which principal component is beta amyloid (A). This core is surrounded 
by a nest formed by degenerating neurites, activated microglia and astrocytes. Other 
substances that conform the SP are the alpha-synuclein (principal not amyloid component), 
alpha 1 antichymotrypsin, alpha 2 macroglobulin, apolipoprotein E, ubiquitin and the 
presenilins. Degenerative neurons are also distinguished around but not in contact with the 
plaques. According his appearance they are classified as: 
a. Difuse. Formed by a delicate network of fine filaments of amyloid fibrils without 
degenerate neurites. Center and its boundaries are not well defined. 
b. Primitive. Are the most common. They are characterized by disordered extracellular A 
deposits wich are poorly  or not fibrillar. Center is not well defined but the borders are 
more accurate. 
c. Classic. Also called neuritic plaques, amyloid have a center surrounded by a crown 
composed of reactive astrocytes, microglia and dystrophic neurites corresponding to 
dendrites and degenerate axons. 
d. Burns. Present only a condensed central amyloid. It has no cellular components. 
These forms represent different developmental stages of the plaques, beginning with the 
accumulation of diffuse amyloid, then it is organized and defined, by associating the 
immune response. Finally, the cellular elements disappear.  
The SP are relatively rare in limbic structures and neocortex and are more visible in frontal 
temporal and occipital regions, while respecting the primary sensorimotor areas. They can 
be found in the brains of people without cognitive deficits, but to a lesser extent (Table 1). 
Higher concentrations are criteria for pathological diagnosis of AD. 
 
Age (years) Amount 
Less than 50 Less than 5 
Between 50 and 65 Less than 9 
Between 66 and 75 Less than 11 
More than 75 Less than 16 
Table 1. Amount of Senile Plaques (SP) per mm3 with 200x augmentation. 
We can now follow the progression of A in vivo deposits using Carbon-11-Pittsburgh 
Compound B Positron Emission Tomography (PIB-PET) which correlates with the number 
of SP. This technique shows a broader distribution in both normal subjects and patients with 
AD. One study (Engler et al., 2006) compared the PIB-PET signal between healthy controls 
and patients with AD found that was higher in patients. Unexpectedly, the most notable 
www.intechopen.com
  
Alzheimer’s Disease Pathogenesis-Core Concepts, Shifting Paradigms and Therapeutic Targets 
 
6 
difference was found in the striatum. Other regions with significant differences were the 
frontal, temporal and occipital lobes. By repeating the test after two years, there was only 
one significant difference in the occipital cortex of patients with AD. The PIB-PET signal 
change did not correlate with the progression of cognitive impairment suggesting that, after 
an initial period, A deposits stabilizes. 
Some familiar forms as mutations of presenilin 1 that cause variant-AD have atypical SP 
that coexists with the usual. There are Cotton Wool plaques, non cored and devoid of 
dystrophic neurites. The distribution is also uncommon, presenting high concentrations 
in the interhemispheric motor cortex representing the lower extremities, which is 
consistent with early-onset spasticity that often accompanies memory and visuospatial 
disorders (Koivunen et al., 2008). 
2.2.2 Neuro-fibrillary tangles (NFT) 
Neurons present an accumulation of flame-shaped inclusions and sometimes form a 
elongated basket around the nucleus. The inclusions are basophils to the hematoxylin and 
eosin and strongly stained with silver stains. The inclusions fill the cytoplasm, particularly 
in the soma and apical dendrite causing neuronal death mainly by apoptosis. Finally there 
are only remnants of the cytoskeleton, such as ghosts´ nodules. 
Development of new staining techniques to visualize phosphorylated Tau protein (Tau-p) 
while they are soluble, in early states called pre-fibrillar, is the basis for classification 
according to the developmental stages of Braak, which suggested changes in the 
pathological diagnostic criteria (figure 3). 
The NFT is distributed in very characteristics areas as the entorhinal and perirhinal 
allocortex, CA1 region of hippocampus and the amygdala. Also found in the nucleus basalis 
of Meynert, Temporal isocortex (areas 20 and 21 of Brodmann) and the rest of the 
hippocampal structures. The NFT coincide with the SP in fronto temporal regions but their 
presence is lower in not limbic structures. 
Recent studies in patients with AD show that less than one third of cases had a "pure" 
disease, being more frequent association of SP and NFT with vascular lesions (50%) or Lewy 
bodies (20 %). 
2.2.3 Vascular changes 
Over 80% of patients have cerebral amyloid angiopathy, which affects the pial vessels of the 
brain and especially the capillaries, which become refined, atrophic, fragmented and 
distorted. Endothelial basement membrane is thickened and disrupted, with amyloid 
deposits and collagen which is associated with an inflammatory response that includes the 
vascular endothelium, perivascular microglia, pericytes and astrocytes, interfering with the 
functioning of the blood-brain barrier (BBB) (Bowman et al., 2007). 
The muscular layer shows segmentary contractions and peripheral vascular plexus is 
impaired or absent. Often these changes are accompanied by ischemic or hemorrhagic 
lesions. 
A meta-analysis included 5 studies and 450 patients (Cordonnier and van der Flier, 2011) 
finds that in 23% of cases are characterized by microbleeding with focal leakage of 
hemosiderin from small abnormal blood vessels. Microbleedings prevalence is higher in AD 
patients than in subjects with mild cognitive impairment, while in the general population is 
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rare. The microbleedings are distributed in cortico-subcortical regions predominantly in the 
occipital lobe, a pattern shared with amyloid angiopathy (Zlokovic, 2008). 
 
 
Fig. 3. Schematic representation of a hemisphere of a normal subject (left) and a hemisphere of 
a person with AD (right). A scale of colors represent the Braak´s NFT stages. The first stages 
are entorhinal (I and II) with absent or mild symptoms. Stages III and IV are called limbic and 
are associated with memory deficit (which influences the intellectual reserve) and subtle 
changes of personality. In cortical stages (V and VI) adding further deterioration in neocortical 
regions with the reverse pattern of myelination, affecting primarily the association areas and 
finally the primary areas. The stages of senile plaques are represented in the top.  
2.2.4 Other less specific findings include 
 Inclusions and pigments: Lipofuscin, Hirano bodies (actin) and Lewy bodies (alpha 
synuclein). 
 Granulovacuolar degeneration: The presence of intra-neuronal vacuoles (3 to 5 microns) 
that can be associated or not with NFT. It is mostly found in the hippocampus. 
 Other: satellitosis, neuronofagia and fragmentation are stages of neuronal death 
mediated by glia. 
3. Genetics 
The AD is an entity with genetic and clinical heterogeneity. There are familial and sporadic 
forms (Table 2). 
3.1 Familial AD 
The familial AD forms are relatively rare, less than 10% and have an autosomal dominant 
pattern. The debut occur at an early age (Early Onstet AD or EAOD), characterized by 
cognitive impairment associated with other neurological signs such as spasticity, motor 
control disorders, ataxia and seizures. 
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Debut  Chromosome Herency Product 
Early Onset Alzheimer Disease (EOAD) 
28-50 14 
Autosomal 
Dominant 
Presenilin 1 
40-50 1 
Autosomal 
Dominant 
Presenilin 2 
55-65 21 
Autosomal 
Dominant  
amyloid precursor protein (APP) 
Late Onset Alzheimer Disease (LOAD) 
Later or never 19 
Autosomal 
Recesive 
Apolipoprotein E4 
Table 2. Relation between genotype and phenotype in Alzheimer´s Disease (AD) 
3.1.1 Amyloid Precursor Protein (APP) 
The first advances in the understanding of genetic factors related to the AD began with the 
discovery of the Amyloid Precursor Protein (APP) in brain of carriers of Down syndrome 
with cognitive impairment. The gene encoding this protein is located in the 21q21 locus and 
is inherited in an autosomal dominant pattern of early onset. More than 32 missense 
mutations have now been described in 85 families. 
The APP gene encodes by alternative splicing. The larger form is a polypeptide of 770 amino 
acids. Alternative splicing of exon 7 encoding the Kurnitz domain and exon 8 encoding the 
OX-2 antigen wich is a polypeptide of 695 amino acids that predominate and other of 751, 
less frequent. So far their function is unknown, although presumably involved in the 
regulation of neuronal plasticity and signal transduction. 
3.1.2 Presenilin 1 (PSEN1) 
Presenilin (PSEN) is the major component of the gamma-secretase. The Locus of PSEN1 was 
found on chromosome 14q24.2. The PSEN1 is a polytopic membrane protein that forms the 
catalytic center of the gamma-secretase complex. Other functions independent of A are the 
acidification of vacuoles by the addition of ATPase, required for autophagy, calcium 
regulation and stimulation of neuronal growth and survival (Pimplikar et al., 2010). 
Depending on the PSEN1 mutation type may be an increase or decrease in the production of 
beta-amyloid. Missense mutations of PSEN1 have full penetrance and are the most common 
cause of early-onset familial AD, between 25-65 years, causing the more severe clinical 
forms. 
3.1.3 Presenilin 2 (PSEN2) 
The locus is located on 1q42.13. PSEN2 is expressed in a variety of tissues including the 
brain, primarily in neurons. Their mutations are rare and only 14 variants have been 
described in six families. 
3.1.4 Apolipoprotein E epsilon (APOE-ε) 
The role of variations in the gene APOE-ε on chromosome 19q13.2 as a risk factor for late 
onset AD has been demonstrated. Its variations are associated with both late-onset familial 
AD and 20% of sporadic AD. 
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This gene has multiple alleles: E2, E3 and E4. In both, normal subjects and AD patients the  
least common is E2 and the most common is E3, but in subjects with AD the E4 allele has a  
frequency almost equal to E3. In its heterozygous composition APOE-ε4 gene increases the 
risk four times, with onset between 5 and 10 years earlier. 
In subjects homozygous for APOE-ε 4, the risk is increased fifteen times with onset between 
10 and 20 years earlier. It is noteworthy that 42% of patients with LOAD have not alleles 
APOE-ε 4 as its absence does not rule out the disease. 
Under normal conditions, APOE is produced predominantly in astrocytes, whereas under 
stress neurons are the main source. APOE  participates in the distribution and metabolism of 
cholesterol and triglycerides. APOE-ε 4 is less efficient than E2 and E3 variants for the 
reuptake and efflux of cholesterol in neurons and astrocytes. On the other hand, APOE-ε4 is 
more efficient for the aggregation of beta-amyloid. 
3.2 Sporadic AD 
Sporadic forms have onset of symptoms later, over 60 years (LOAD). A large proportion of 
these cases have a family history of dementia suggesting a strong genetic component. On 
the other hand, the history of a first degree relative diagnosed with AD increase the risk of 
AD from two to seven times. 
Attempts to demonstrate associations between genetic variations and sporadic AD others 
than APOE-ε4 has been inconsistent and rarely replicated. This scenario has been changing 
over the past three years with the results of studies of Genome Wide Association Studies 
(GWAS). 
An article that reviews 15 GWAS (Bertram et al., 2010) confirms once again the relevance of 
the APOE gene variations as the most important risk factor in sporadic AD. At the same 
time new candidate genes have begun to emerge. Among the most notable are genes 
involved in beta-amyloid metabolism: Ataxin1 (ATX1), Siglec33 (CD33), Clusterin aka 
Apolipoprotein J (CLU-APOJ), Complement Component (3b/4b) receptor 1 (CR1); 
regulators of Tau phosphorylation: GRB2-Associated Binding Protein 2 (GAB2) and 
modulators of synaptic transmission as Protocadherin11 X linked (PCDH11X) and Inositol 
Phosphatydil Clathrin Assembly Binding Protein (PICALM). 
However, it is appropriate to remember that these new variants increase the risk only from 
0.10 to 0.15 times suggesting that, rather than the independent effect should be referred to 
the impact of gene networks. Overall, mutations in APOE and new variants described and 
confirmed could justify up to 50% of cases of sporadic AD. 
Neuro Image Alzheimer's Disease Initiative (ADNI) extends the capacity of association 
between genetic variants and phenotypes of the AD because provides data from 
neuroimaging and other biomarkers. One of the most interesting findings of this study is the 
linear relationship between the number of alleles PICALM G and thinning of the entorhinal 
cortex, an effect that is independent of APOE variants (Saykin et al., 2010). 
4. Pathogenesis 
Traditionally attention has focused on the typical lesions and its primary components: the 
A of the SP and tau protein in the NFT, examining the impact that the accumulation of 
these compounds in different parts of the brain tissue. Currently the research focus has 
shifted to the initial and solubles states of both metabolic pathways: amyloid cascade and 
tau phosphorylation, trying to unravel the relationship between them and their earlier 
effects.  
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4.1 Amyloid beta metabolism 
The A is a small peptide fragment of a transmembrane protein called amyloid precursor 
protein (APP). This protein is found in cytoplasmic membranes, endosomal and Golgi 
system of the nervous system and blood cells. Both the APP and its products, including 
the A can also be located in mitochondria. Certain isoforms of APP have a domain 
protease inhibitor Kunitz regulating the coagulation cascade. In normal subjects the A 
peptide is fragmented by a protein alpha-secretase which divides into two segments 
forming nexin II modulator action of coagulation and the A of 16 amino acid peptide 
highly soluble. 
This A peptide binds to alpha 2 macroglobulin, which signals the proteins to be degraded 
and form a A-A2M complex that binds to a protease. The product of these interactions is 
reintroduced into the nerve cell to adhere to them first through A2M for the membrane 
receptor that is common to LDL and APOE. 
There is an alternative way that is the complete detachment of the peptide A 40 to 42 
amino acids. This occurs by the action of beta-secretase BACE (division 1) and gamma-
secretase (split 40-42). The gamma secretase is composed of four segments: presenilin, 
nicastrin, APH-1 PEN2 and presenilin, the active site. A 1-42 segments are more difficult 
to degrade and tend to aggregate to form oligomers (OM). Monomers do not produce 
damage, however, since dimers formed are capable of causing cell death mediated by 
microglia.  
Although OM can be composed of aggregates of 2 to 100 peptides, the most frequents are 
the compounds for 3 to 7 segments. Unlike the SP, which are usually away from the 
regions of greatest damage, the OM has a wider distribution and can cause functional and 
structural changes in regions typically affected in AD, for example the entorhinal cortex 
and CA1, respecting initially CA3 and Cerebellum. Synapse loss and cognitive 
impairment correlates well with the concentration of OM, but not with SP. On the other 
hand, the OM may diminish or even abolish Long Term Potentiation (LTP), an effect that 
is selective because it does not affect Excitatory Post Synaptic Potential (EPSP) or Long 
Term Depression (LTD).  
Apparently these changes in electrical activity are mediated by prion receptors PrPc, molecules 
with which the OM have a high affinity. Indeed, blocking these receptors with anti-PrPc 
antibodies can reverse the behavioral and learning disorders in experimental models of AD in 
mice (Chung et al., 2010). Larger aggregates called Proto fibrils (PF) are also able to induce 
toxicity and cell death, however, these molecules are less stable (Klein, 2002). 
Apolipoprotein J (APOJ) secreted by astrocytes may prevent the formation of PF, but not 
of OM, in fact facilitates their aggregation by increasing the substrate and serve as a 
chaperone. Interestingly, Clum-APOJ mutations are well replicated as risk factors in 
GWAS studies. 
Finally, the formation of insoluble fibrils, whose center is composed of 1-42 A which is then 
added A 1-40, accumulates in the interstice where suffers the loss of helical conformation 
(alpha helix) to adopt a beta sheet conformation, very difficult to degrade. These complexes 
achieve stability by association with several proteins, including SAP (Serum Amyloid 
Component) very stable and only degradable in the liver and accompanying amyloid 
deposits from any source (Figure 4A). The presence of these bodies cause the activation of 
the immune system, especially the microglia, which perpetuate the inflammation and injury 
by free radicals. 
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Fig. 4. A) The amyloid beta is part of a transmembrane protein whose end is intracellular 
NH3 and extracellular COOH. Cleavage by alpha and gamma secretases produces a peptide 
16-42 very soluble and easily degradable. The alternative cleavage by beta and gamma 
secretases produces insoluble 1-42 peptide, then added in formation of folded sheets, very 
difficult to degrade.   
B). Tau proteins are part of the microtubule-associated proteins. The hyperphosphorylation 
of these proteins causes a disruption of the cytoskeleton engaging features such as 
maintaining the structure and intracellular transport. Hyperphosphorylated tau proteins 
forming paired helices very difficult to degrade. This eventually leads to neuronal death and 
depopulation. 
4.2 Neurofibrillary metabolism 
The NFT are mainly composed of paired helical filaments formed by hyperphosphorylated 
tau protein. They are also formed by other proteins such as MAP2 (predominantly in 
dendrites), ubiquitin, and A peptides, supporting the theory of amyloidogenesis as a 
primary lesion. 
Tau proteins predominate in axons and form the group of MAP (Microtubule Associated 
Protein) interacting with microtubules during cell movement and transport assembling or 
disassembling the microtubules depending on whether there lengthening or shortening of 
the extensions, especially in axons. Recent research has found that tau proteins are also 
located in the dendrites, although in a much lower concentration. Here are involved in 
cytoskeletal functions and signal transduction by facilitating the activity of protein tyrosine 
kinase FYN (FYN), which phosphorylates the 2B subunit of N-Methyl-D-aspartate (NMDA) 
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receptors, mediating their interaction with Protein Posinaptic Density (PSD-95). This 
interaction is critical for the efficiency of the synapse and in its absence there is a decrease of 
experimental seizures (Ittner et al., 2010).  
Tau hyperphosphorylation has several effects. First results in their haste and self-
aggregation forming, in the case of AD paired helical filaments that impede axonal 
transport. On the other hand, Tau-p have a greater affinity for FYN and thereby increase its 
concentration in the dendrites. This leads to a shift in the concentration of Tau protein from 
the axon to the dendrites, finally occupying the soma and breaking the cell dynamics 
leading eventually apoptotic neurodegeneration (figure 4 B).  
An interesting question is why does the progression and spread of Tau-p follows a route so 
stereotyped as proposed in the anatomical and pathological Braak´s stages? 
In our view there are two possible answers: 
1. This pattern shows a gradient of susceptibility to increasing exposure to an aggressor 
factor. In this case the obvious candidate would be the OM. However, as we have seen, 
after a first phase, the deposition rate of A and PIB-PET load stabilizes, while the 
spread and damage induced by Tau-p continues at the same time that the neuronal loss 
and cognitive impairment  
2. Tau-p molecules and their aggregates do not require external factors, but these 
formations have a prion-like behavior. Tau-p are seeds that can penetrate the cell and 
recruit Tau functional molecules making them hyper-phosphorylated forms. Thus 
continues the cycle of aggregation and spreading the damage to other areas. 
The latter possibility seems to be reinforced by an experimental model that achieved with 
very small concentrations of Tau-p and in a short time, a degree of infection similar to that 
observed in tissues of patients with AD (prion-like dissemination). (Clavaguera et al., 
2009;Guo and Lee, 2011). 
4.3 Relationship between Tau and A metabolism 
A complex problem is determining which is the primary lesion and the relationship between 
them. There are some facts that suggest that the primary is the A accumulation. For example, 
A accumulation precedes the presence of NFT. Also been achieved KO mice that produce 
accumulation A with all the features of these lesions without neurofibrillary tangles. These 
mice have cognitive deficits comparable to that human AD. Moreover, the demonstration of 
tau protein as a basis for degenerations with dementia that occur (Frontotemporal dementia 
and parkinsonism linked to chromosome 17; Progressive Supranuclear Palsy and Pick's 
dementia) in the absence of SP, support the protagonism of the NFT. 
A very interesting hypothesis has been proposed by Ittner and Gotz, called “Tau Axis 
Hypothesis” (Ittner and Gotz, 2011). Here suggest that the presence of Tau protein in the 
dendrite is essential for OM mediated toxicity. In fact, in experimental models the absence of 
interaction Tau-FYN prevents the development of cognitive, behavioral disorders or 
neuronal degeneration induced by OM. On the other hand, increasing the concentration of 
OM increases the phosphorylation of Tau protein, which moves them to the dendrites and 
increases its affinity for FYN, closing a vicious circle. 
4.4 Vascular factors 
The frecuent presence of vascular lesions in patients with AD and the results of 
epidemiological studies suggest that vascular risk factors increase the likelihood of suffering 
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from AD and once established, accelerate the progression of cognitive impairment. The most 
important are hypertension, advanced age, atherosclerosis, homocystinemia, 
hyperlipidemia, metabolic syndrome and obesity. Cerebral vascular lesions, especially 
lacunar infarcts increase to double the risk of AD (Ott et al., 1999). 
It also showed that cerebral hypoperfusion precedes onset of clinical dementia and that the 
reduction in cerebral blood flow (CBF) occurs before cognitive impairment and 
hippocampal atrophy. This is consistent with results achieved by our group. 
The Nun Study (Snowdon et al., 1997) relates the number of vascular lesions with the 
severity of Alzheimer's disease by showing that individuals with one or two lacunar 
infarctions had a greater cognitive deterioration than individuals who had no stroke, 
regardless of the number of neurofibrillary tangles in the cortex. 
Experimental studies in rodents have shown that chronic cerebral hypo-perfusion and 
transient cerebral ischemia increases the production of amyloid peptide precursor, beta 
amyloid protein and the accumulation of hyperphosphorylated Tau protein, which 
simulates the changes of Alzheimer's disease. However, these conditions of intense ischemia 
are not present in normal subjects or patients with AD.  
The beta amyloid peptide has a vasoconstrictor effect, which could be related to the early 
decrease in CBF and the narrowing of the average diameter capillary. In AD the mean 
diameter capillary is decreased, which is associated with cognitive impairment even before 
the accumulation of SP and NFT.  
In the AD there is an increase of Advanced Glycation End products (AGE) that accumulate 
on the walls of blood vessels. In addition, the concentrations of AGE receptors (RAGE) are 
several times increased in vessels, microglia and neurons. The binding of A to RAGE in the 
luminal membrane of the BBB leads to the peripheral A input in to the brain followed by 
binding to neurons. Increased RAGE becomes a pro-inflammatory signal that activates 
microglia (Zlokovic, 2008).  
Low density lipoprotein receptor related protein 1 (LRP) is a member of the family of LDL 
and a major clearance receptor for A at the BBB. LRP concentrations decline with age and 
are particularly low in the elderly and patients with AD.  
BBB dysfunction is early and confirmed by a series of morphological changes such as 
reducing the number of mitochondria, tight junctions, loss of pericytes and the presence of 
pinocytotic in cerebral microvessels.  
In a clinical study showed the BBB impairement in 22% of patients with AD (Bowman et al., 
2007). The rate of damage progression was measured by concentrations of albumin in 
Cerebrospinal Fluid (CSF) and correlated with worsening of cognitive performance.  
Cholinergic nuclei, dramatically affected in AD, have a regulatory effect on CBF, 
particularly groups of the substantia innominata and the Nuclei basalis magnocellularis 
(SI / NBM). In healthy volunteers who were given Scopolamine, the CBF decreased from 
20%.  
The opposite effect was found in an experimental study where chronic deep electrical 
stimulation of the region SI / NBM produced a sustained increase in CBF in basal ganglion 
and Cortex, particularly in fronto parietal regions. 
4.5 Cerebral insulin resistance 
Insulin in the brain plays an important role in regulating metabolism, and alterations in 
activity are directly related to metabolic diseases such as obesity, diabetes or metabolic 
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syndrome. In the mammalian brain, insulin induces anorexia, weight loss and regulates the 
hypothalamic control of food intake. 
The insulin receptor (IR) is a glycoprotein of 300 to 400 kDa, formed by two identical alpha 
chains located in the extracellular region and two beta subunits that end within the cytosol, 
the beta chains have intrinsic tyrosine kinase activity. The IR is found in higher 
concentrations in neurons when compared with the glial cells. The IR is distribuited at the 
brain structures in different densities, they expression have proved at the olfactory bulb, 
hypothalamus, pituitary, choroid plexus, thalamus, piriform cortex, hippocampal formation, 
amygdaloid nuclei, prefrontal cortex and cerebellum. The IR largest concentrations are at 
the level of the olfactory bulb, hypothalamus, hippocampus and cerebellum.  The IR is 
widely found in the synapses, especially in the dendritic tree where it regulates 
neurotransmitter release and the recruitment of receptors.  
Within the brain, function of Insulin / Insulin like Growth Factor (IGF) include stimulation 
of neuronal and oligodendroglial survival, growth factor, regulation of mitochondrial 
function and energy metabolism, expression of Tau and acetylcholine transferase.  
The IGF2 is abundantly expressed in the hippocampus. Recent research shows that IGF2 
plays an essential role in the regulation of LTP and memory consolidation, one of the 
cognitive functions affected in early stages of AD (Chen et al., 2011).  
The search for an association between insulin metabolism and AD brain has been 
extensively investigated in recent years.  The starting point takes place in epidemiological 
studies wich strongly indicate that diabetes mellitus (DM) is a risk factor for AD. A closer 
look identifies insulin resistance as risk factor independent of changes in blood sugar levels. 
In people with insulin resistance and cognitive impairment without DM there is a reduction 
in the rate of cerebral glucose utilization. This pattern is also different in people with DM 
type 2 or pre DM during the execution of cognitive tasks, suggesting that insulin resistance 
could be taken as an early marker of AD (Baker et al., 2011). 
Unlike the vascular brain disease that affects mainly CA1, a region highly susceptible to 
ischemia, insuline resistance selectively damaged the entorhinal cortex, one of the first areas 
involved in AD. 
Biochemical and genetic data show that insulin degrading enzyme (IDE) is involved in 
insulin and A homeostasis. The expression and activity of IDE is significantly decreased in 
AD brains compared with age-matched controls. In addition, IDE and A are deposited in SP 
and vessels, indicating a gross conformational change by post-translational mechanisms. These 
changes in the distribution and activity of IDE may result in hormone resistance, insufficient 
degradation of insulin and A, formation of A oligomers and neurodegeneration. 
The possibility that the AD is the result of a selective insulin resistance in the brain has been 
proposed by de la Monte et al. with solid clinical and experimental arguments that 
crystallize into a new concept: the DM type 3 (de la Monte and Wands, 2008).  
In post mortem studies of brains affected by AD were significant decreases in concentrations 
of Insulin and Insulin like Growth Factor (IGF). By comparing the expression of IGF with 
Braak´s stages shows that the involvement is early and progressive decline increasingly as 
they progress Braak´s stages, what is more remarkable for IGF1. 
Streptozocin experimental models in rats lead to a selective reduction of the expression of 
insulin / IGF in the brain without changing peripheral levels of glucose or insulin. In these 
animals are changes similar to the AD such as increased BA, Tau phosphorylation, 
neurodegeneration and gliosis and decreased genes associated with neurons, 
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oligodendroglia, and acetyl choline transferase,  while increase genes related to microglia 
and inflammation (de la Monte and Wands, 2008). 
Other factors that may have some weight in neuronal loss and progression of damage are: 
the development of inflammatory changes, damage to mitochondria, the energy imbalance, 
the increased production of free radicals, the problems of calcium metabolism, the toxicity of 
some elements such as aluminum, inefficient autophagy and suppression of neurogenesis. 
5. Clinical expression 
As we have seen, there are many factors which interact and are interwoven pathways, 
increasing the capacity of injury in different brain areas, which is expressed as a progressive 
cognitive deficit, which begins as a disorder of recent memory and then progresses to affect 
in advanced stages, the majority of brain functions. Each pathway described above can be 
added to the final damage but there are two main theories that justify the initial cognitive 
deficits of AD, these are: The "Theory of cortical disconnection" and "Cholinergic theory". 
5.1 Theory of cortical disconnection 
Neurofibrillary tangles in the entorhinal cortex, wich is the cortical portal of the 
hippocampus, are distributed in layers II, which together with the layer III form the 
perforant pathway to the hippocampus and the layer IV receiving eference from the 
hippocampus. In this way hippocampus is isolated from the neocortex. This adds to the 
deficit of glutamate and other neuropeptides such as neuropeptide Y, oxytocin, vasopressin 
and somatostatin in the association cortices adding a cortico-cortical disconnection that 
correlates with aphasia, apraxia and agnosia, as well as visuospatial and executives 
disorders. At first the degeneration is slight and apparently can be offset by the cognitive 
reserve, however, as neurodegeneration progresses, this mechanism is not sufficient.        
The techniques of functional magnetic resonance imaging at 7 Tesla can define in vivo the 
degree of atrophy of specific regions of the hippocampus (Kerchner et al., 2010).. 
5.2 Cholinergic theory 
In advanced stages there is a decrease of over 90% of the activity of acetylcholinesterase 
which identifies a dramatic impairment of the cholinergic system in this disease. This causes 
early and progressive memory affection. One study suggests that progression of cholinergic 
deficit is not linear but at an early stage levels rise, falling years later. This is similar to what 
occurs with serotonin (Dekosky et al., 2002).  
The selective degeneration of the nucleus basalis of Meynert, principal cholinergic eference 
to neocortex and septal nuclei and diagonal band of Broca, subcortical cholinergic eference, 
especially to the hippocampus, cause a progressive anterograde memory. Some authors 
hypothesize that the clinical expresion of depression needs some indemnity of cholinergic 
pathways, close to normal levels, which occurs only in initial stages.  
As mentioned before, there is evidence of early changes in regional CBF, which could be 
related to the degeneration of cholinergic population that has a regulatory effect. This is 
known as the cholinergic-vascular theory.  
As part of a research project in our institution (International Center of Neurological 
Restauration-CIREN), and with the collaboration of other Cubans institutions, we compared 
the global cerebral blood flow (gCBF) in absolute units (ml/min/100 g) at resting state 
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between 38 controls and 40 amnestic MCI subjects, both groups with similar demographic and 
vascular risk factors (limited). We explored also a possible association between gCBF and 
cognitive function, after controlling for age, gender, level of education and global brain 
atrophy (quantified on 3D T1-weighted MRI images). gCBF was measured by spectral analysis 
of radionuclide angiography, which is a simple and non-invasive method for the 
quantification of gCBF (Murase et al., 1999;Van et al., 2001) and linearly correlated with gCBF 
measured by using PET (Takasawa et al., 2004). Our results show a significant decrease of 
gCBF in the MCI group as compared with controls (p < 0.05, Mann-Whitney U Test, figure 5).  
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Fig. 5. MCI group show less gCBF than control group. 
We also found in the MCI group a direct association between gCBF and semantically 
unrelated word-pairs learning (immediate recall) as measured by the hard-word pairs 
learning score of the Wechsler memory scale (Spearman R = 0.46, p < 0.005, figure 6), after 
removing the effects of age, gender, level of education and global brain atrophy 
(standardized z_scores). Control subjects show no association.   
Interestingly, other domains of cognitive function (attention, episodic memory, working 
memory, verbal fluency, praxis and executive function) show no association with gCBF.  
Thus verbal learning is probably more sensitive than other cognitive functions in MCI 
patients, particularly semantically unrelated word-pairs learning. Many studies have 
reported very early deficits in associative memory in MCI patients, which is the ability to 
associate unrelated items presented together during the encoding phase, or to associate one 
item to its spatial or visual context (Belleville et al., 2008). 
The decrease of gCBF observed in our MCI group cannot be explained by a clear vascular cause, 
related to demographic variables or brain atrophy. One possible explanation of our findings 
could be to assume a gradual reduction of cholinergic vasodilatory innervations of cerebral blood 
vessels as a result of a gradual cholinergic deficit originating in the basal forebrain, which also 
affect learning and memory (Schliebs and Arendt, 2006). This assumption is supported by 
previous studies (Claassen and Jansen, 2006;Farkas and Luiten, 2001). 
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A way to confirm a gradual reduction of regional vasodilatory innervations in the MCI state 
would be to study the cerebrovascular reserve and find out the connection with cognitive 
decline. This study will be the subject of further research. Perhaps a more complete 
evaluation of this topic could be the combined studies in the same MCI subjects (or 
equivalent animal model) of cerebral blood flow and direct measurements of cholinergic 
activity and plaque formation (for example, using PET imaging). Recent studies suggest an 
interaction between vascular, cholinergic and “amyloid β” hypotheses of AD.   
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Fig. 6. There is a positive correlation between gCBF and semantically unrelated word-pairs 
learning in the MCI group.  
5.3 Role of others neurotransmitters 
Other neurotransmitter imbalances better explain the non-cognitive symptoms. As 
mentioned, there is a greater involvement of the raphe nuclei, the nucleus ceruleus and a 
relative sparing of the substantia nigra.  
Serotonin deficit. It is related to depressive symptoms as well as obsession, compulsion and 
aggression. This is observed both in AD and in normal people. A study with Fluoro-
benzamidoethylpiperazine-PET shows that in Mild Cognitive Impairment patients exists 
up-regulation of hippocampal serotonin, apparently as a compensatory mechanism. Once 
the AD is stablished, serotonin levels falls.  (Truchot et al., 2007). 
Noradrenaline deficit. It is also observed associated with depression and psychomotor 
agitation. With this neurotransmitter occurs something unique because although there is a 
depoblaction of nucleus ceruleus (where there are Lewy bodies), there is a cortical 
noradrenergic hyperactivity, which is attributed to an increased sensitivity and the 
production of cortical noradrenaline. The increased sensitivity is observed in the prefrontal 
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cortex and in the hippocampus. However, the increased concentration of noradrenaline is 
only found in the prefrontal cortex. In cases of depression there is noradrenaline decrease, 
while those with agitation there is an increase.  
Relative dopamine preservation. This causes an imbalance choline / dopamine with the 
relative increase of the latter, a substrate of observed hallucinations, sleep disorders and 
psychosis. In 30% of AD patients there is a decrease of dopamine with the presence of a 
parkinsonian syndrome. However, the preservation of posture and gait to advanced stages 
is a characteristic of cortical dementia. 
6. Conclusions 
Currently there are notable advances in understanding the basic mechanisms of AD. This 
has allowed the design of biomarkers of the disease in vivo wich are able to define its 
presence, with a high degree of sensitivity and specificity, even before establishing the 
cognitive deficits characteristic of this entity. This has led to reconsider the diagnostic 
criteria and include diagnostic tools such as PIB-PET, Magnetic Resonance and 
Cerebrospinal Fluid (Dubois et al., 2007).  
This extends the time for preventive or early intervention, using new treatments designed to 
block the damage in the early stages of the cascade of events. The prevention of risk factors 
and the use of new drugs such as fibrillar aggregation inhibitors, intranasal insulin and anti-
PrPc antibodies promise to change the current scenario, dominated by discrete symptomatic 
treatment gains.   
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